Helminthic therapy and inflammatory bowel disease (IBD)
The anecdotal evidence[edit | edit source]
Many thousands of people are using helminthic therapy to treat Crohn’s disease and colitis, and the following quotes are indicative of the results being achieved.


The following graphic shows the colon of a patient with ulcerative colitis before and after treatment with TSO. (Read the whole paper here.)
See the following links for more visual evidence of the effects of helminths on IBD.
- The effects of TTO on ulcerative colitis
- The effects of NA and TTO on Crohn’s colitis
- The effects of NA and TTO on ulcerative colitis
The following detailed personal stories were written by people using helminths to treat Crohn’s disease or ulcerative colitis.
- Hookworms literally saved my life (Patient with Crohn's disease and Sweet syndrome)
- Hookworms prove life-changing for a patient with ulcerative colitis and Crohn's disease
- TSO tames colitis in a 70 year old
- Crohn's and colitis patient bounces back to health with hookworms and fecal transplants
- Four family members with Crohn's and ulcerative colitis are all delighted with their worms
- TSO successfully treats ulcerative colitis after drugs cause adverse reactions
- Thirteen years and counting: maintaining remission with TSO for colonic Crohn's and IBD-related (non erosive) arthritis
- Rheumatoid arthritis and ulcerative colitis relieved by TSO
- Hookworms successful against colitis and celiac disease after medicine fails
Here are collections of brief reports written by people using helminths to treat IBD.
- Personal stories: Crohn's disease
- Personal stories: ulcerative colitis
- Personal stories: ulcerative proctitis
- Personal stories: microscopic colitis
- Personal stories: pancolitis
These two in-depth video interviews are with people who have successfully treated their Crohn's disease using helminths.
- Clinical remission of Crohn's disease (1 hr 13 mins)
- How worms changed my life. Helminthic therapy for colonic Crohn's disease (57 mins)
The scientific evidence[edit | edit source]
- 2025 Aug 19 Protective and therapeutic potentials of Trichinella spiralis larval antigen in murine induced colitis -- Full text
- 2025 Jun 27 Intact glycoconjugates from Taenia crassiceps excreted/secreted products ameliorate chemically induced colitis by modulating inflammation and strengthening adherens junctions -- Full text
- 2025 Jun 20 Excretory/secretory products from Hymenolepis nana adult worms alleviate ulcerative colitis in mice via tuft/IL-13 signaling pathway -- Full text | PDF
- 2025 Mar 3 Nematode serine protease inhibitor SPI-I8 negatively regulates host NF-κB signalling by hijacking MKRN1-mediated polyubiquitination of RACK1 -- Full text | PDF.
- ... administration of recombinant N. brasiliensis SPI-I8 significantly reduced the impact of colitis on colon length, with no side effects detected.
- 2025 Feb 27 Clonorchis sinensis Infection prevents DSS-induced Colitis Via Lithocholic Acid in a Gut Microbiota-Dependent Manner -- Full text
- 2025 Feb 10 A162 interleukin-4 signaling is not a prerequisite for helminth-therapy protection against colitis -- Full text | PDF
- 2024 Dec 12 Hymenolepis nana antigens alleviate ulcerative colitis by promoting intestinal stem cell proliferation and differentiation via AhR/IL-22 signaling pathway -- Full text | PDF
- 2024 Nov 4 The gut microbiota is essential for Trichinella spiralis-evoked suppression of colitis -- Full text | PDF
- 2024 Oct 15 Immunomodulatory effect of Dicrocoelium dendriticum ova on DSS-induced experimental colitis in C57BL/6 mouse -- Full text | PDF
- 2024 Oct 6 Immuno-therapeutic and prophylactic potential of Trichinella spiralis antigens for inflammatory bowel diseases -- Full text | PDF
- 2024 Oct 4 Helminth-derived proteins as immune system regulators: a systematic review of their promise in alleviating colitis -- Full text | PDF
- 2024 Aug 29 Nippostrongylus brasiliensis alleviates dextran sulfate sodium salt-induced ulcerative colitis in mice: a preliminary study -- Full text (chinese)
- 2024 Aug 13 Echinococcus multilocularis serpin regulates macrophage polarization and reduces gut dysbiosis in colitis -- Full text | PDF
- 2024 Jun 21 Pharmaceutical Potential of Remedial Plants and Helminths for Treating Inflammatory Bowel Disease -- Full text | PDF
- 2024 Jun 18 Helminth-derived biomolecules as potential therapeutics against ulcerative colitis -- Full text
- 2024 Jun 15 An insight into the gut microbiota after Schistosoma japonicum eggs immunization in an experimental ulcerative colitis model -- Full text
- 2024 Mar 30 The GAPS Nutritional Protocol As a Dietary Treatment for Inflammatory Bowel Disorders: Analysis of Eight Case Studies (Mentions helminthic therapy)
- 2024 Jan 3 Galectin from Trichinella spiralis alleviates DSS-induced colitis in mice by regulating the intestinal microbiota -- Full text | PDF
- 2023 Nov "Out of the box" new therapeutic strategies for Crohn´s disease: moving beyond biologics -- Full text
- 2023 Aug 14 Inhibition of GSDMD-mediated pyroptosis triggered by Trichinella spiralis intervention contributes to the alleviation of DSS-induced ulcerative colitis in mice -- Full text | PDF
- 2023 June 15 Controlled Hookworm Infection for Medication-free Maintenance in Patients with Ulcerative Colitis: A Pilot, Double-blind, Randomized Control Trial -- Full Text | PDF
- 2023 Apr 18 Helminth Lessons in Inflammatory Bowel Diseases (IBD) -- Full text | PDF
- Treatment of moderate to severe IBD involves the use of immune modulators and/or biologics, which have several toxicities and side effects, such as predisposition to infections, cancer, and demyelinating diseases in addition to others. Helminths or helminth products are attractive therapeutic avenues given their safety profile.
- 2023 Jan 23 Nematode-Induced Growth Factors Related to Angiogenesis in Autoimmune Disease Attenuation -- Full text | PDF
- 2023 Jan 18 Protection from T cell-dependent colitis by the helminth-derived immunomodulatory mimic of transforming growth factor-β, Hp-TGM -- Full text | PDF
- 2022 Dec 9 The impact of Helicobacter pylori and intestinal helminth infections on gastric adenocarcinoma and inflammatory bowel disease in Sub-Saharan Africa -- Full text | PDF
- 2022 Nov 30 Following the Indian Immigrant: adoption of westernization results in a western gut microbiome and an increased risk of inflammatory bowel diseases -- Full text
- 2022 Nov 20 Schistosoma japonicum Eggs Exerts Protective Effects in an Experimental Ulcerative Colitis Model -- Full text
- 2022 Oct 27 Echinococcus granulosus sensu stricto and antigen B may decrease inflammatory bowel disease through regulation of M1/2 polarization -- Full text
- 2022 Oct 11 Protective effect of Schistosoma japonicum eggs on TNBS-induced colitis is associated with regulating Treg/Th17 balance and reprogramming glycolipid metabolism in mice -- Full text | PDF
- 2022 Sept 9 Cysteine protease of Clonorchis sinensis alleviates DSS-induced colitis in mice -- Full text | PDF
- 2022 Jun 24 "Out of the box" new therapeutic strategies for Crohn’s disease: moving beyond biologics | PDF
- 2022 May 24 Prevalence and Associated Risk Factors of Intestinal Parasitic Infections among Egyptian Patients with Inflammatory Bowel Disease -- Full text | PDF
- 2022 Apr 19 AntigenB drives M1/M2 polarization following Echinococcus granulosus infection in inflammatory bowel disease (preprint)
- 2022 Jan Potential of human helminth therapy for resolution of inflammatory bowel disease: The future ahead
- The authors conclude that most of the currently available IBD therapies expose patients to substantial risk, whereas helminths will likely prove to be safe in therapeutic applications and that the administration of helminhs such as T. suis offers an approach to treating IBD with little risk of serious complications.
- 2021 Dec 14 Recombinant protein Schistosoma japonicum-derived molecule attenuates dextran sulfate sodium-induced colitis by inhibiting miRNA-217-5p to alleviate apoptosis -- Full text | PDF
- 2021 Sept 28 Use of helminth therapy for management of ulcerative colitis and Crohn's disease: a systematic review
- The aim of this systematic review was to investigate whether there is evidence to support the use of helminth therapy for the management of Crohn's disease and ulcerative colitis… all nine studies concluded helminth therapy was safe and tolerable, and therefore there is currently no evidence against further exploration of this treatment option.
- 2021 Sept 13 Cooperation between host immunity and the gut bacteria is essential for helminth-evoked suppression of colitis -- Full text
- 2021 Sept 6 Schistosoma japonicum peptide SJMHE1 inhibits acute and chronic colitis induced by dextran sulfate sodium in mice -- Full text | PDF
- 2021 Aug 6 Infection with Hymenolepis diminuta Blocks Colitis and Hastens Recovery While Colitis Has Minimal Impact on Expulsion of the Cestode from the Mouse Host — Full text
- 2021 May 26 Synthetic hookworm-derived peptides are potent modulators of primary human immune cell function that protect against experimental colitis in vivo -- Full text | PDF
- 2021 Feb Helminth-induced regulation of T-cell transfer colitis requires intact and regulated T cell Stat6 signaling in mice -- Full text
- 2020 Dec The role of helminth and microbiome-derived metabolites in the healing of inflammatory bowel diseases related wounds in vitro -- PDF (thesis)
- 2020 Oct 2 Excretory/Secretory Products From Trichinella spiralis Adult Worms Attenuated DSS-Induced Colitis in Mice by Driving PD-1-Mediated M2 Macrophage Polarization -- Full text | PDF
- 2020 Aug 20 Succinate Produced by Intestinal Microbes Promotes Specification of Tuft Cells to Suppress Ileal Inflammation (IBD)
- 2020 Jun 11 Extracellular Vesicles Derived From Trichinella spiralis Muscle Larvae Ameliorate TNBS-Induced Colitis in Mice -- Full text | PDF
- 2020 May 5 Systematic review: gastrointestinal infection and incident inflammatory bowel disease -- Full text
- 2020 Jan 24 Wuchereria bancrofti macrophage migration inhibitory factor-2 (rWbaMIF-2) ameliorates experimental colitis
- 2019 Dec 26 Immunomodulation of Murine Chronic DSS-Induced Colitis by Tuftsin-Phosphorylcholine -- Full text
- 2019 Dec 24 Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM) -- Full text (see also 08/12/2021 Compréhension du mécanisme d'action de la P28GST dans le traitement des maladies inflammatoires auto-immunes (thesis in French)
- 2019 Dec 13 Immunomodulatory effect of Syphacia obvelata in treatment of experimental DSS-induced colitis in mouse model
- 2019 May 28 Schistosoma mansoni worm infection regulates the intestinal microbiota and susceptibility to colitis
- 2019 Mar 14 Therapeutic Potential of Helminths and Helminth-Derived Antigens for Resolution of Inflammation in Inflammatory Bowel Disease (IBD)
- 2019 Jan 22 Macrophages treated with antigen from the tapeworm Hymenolepis diminuta condition CD25+ T cells to suppress colitis (HDC)
- 2019 Jan 4 Exclusive dependence of IL-10Rα signalling on intestinal microbiota homeostasis and control of whipworm infection -- Full text | PDF
- 2018 Sept 25 The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease -- Full text | PDF (IBD)
- 2018 Aug 16 Helminth Antigen-Conditioned Dendritic Cells Generate Anti-Inflammatory CD4 T Cells Independent of Antigen Presentation via MHC II (HDC) (Colitis)
- 2018 Jul SXP-RAL Family Filarial Protein, rWbL2, Prevents Development of DSS-Induced Acute Ulcerative Colitis -- Full text
- 2018 Jul 16 Influence of NOD2 Variants on Trichuris suis ova Treatment Outcome in Crohn's Disease -- Full text | PDF
- 2018 Jun 18 The benign helminth Hymenolepis diminuta ameliorates chemically induced colitis in a rat model system (HDC)
- 2018 May 23 Extracellular Vesicles From the Helminth Fasciola hepatica Prevent DSS-Induced Acute Ulcerative Colitis in a T-Lymphocyte Independent Mode -- Full text | PDF
- 2018 Apr 30 Hookworm Secreted Extracellular Vesicles Interact With Host Cells and Prevent Inducible Colitis in Mice -- Full text | PDF
- 2018 Jan 27 Helminth Therapy: Advances in the use of Parasitic Worms Against Inflammatory Bowel Diseases and its Challenges -- Full text | PDF
- 2018 Jan 4 Young mice expel the tapeworm Hymenolepis diminuta and are protected from colitis by triggering a memory response with worm antigen -- Full text | PDF
- 2017 Winter A Critical View of Helminthic Therapy: Is It a Viable Form of Treatment for Immune Disorders Under the Category of Inflammatory Bowel Disease? Alyssa Murphy, undergraduate thesis
- 2017 Nov 28 Preventive Trichuris suis ova (TSO) treatment protects immunocompetent rabbits from DSS colitis but may be detrimental under conditions of immunosuppression -- Full text | PDF
- 2017 Nov 24 Discovery of potent parasite protein may lead to new therapeutic options for inflammatory bowel conditions Medical News Today (IBD)
- 2017 Oct 16 Orally administered Taenia solium Calreticulin prevents experimental intestinal inflammation and is associated with a type 2 immune response -- Full text | PDF (Colitis)
- 2017 Oct 6 Suppression of inflammation and tissue damage by a hookworm recombinant protein in experimental colitis -- Full text | PDF (NA)
- 2017 Sep 11 Triggering immunological memory against the tapeworm Hymenolepis diminuta to protect against colitis (HDC)
- 2017 Aug 21 Schistosoma japonicum attenuates dextran sodium sulfate-induced colitis in mice via reduction of endoplasmic reticulum stress -- Full text | PDF
- 2017 Mar 10 A recombinant cystatin from Ascaris lumbricoides attenuates inflammation of DSS-induced colitis
- 2017 Feb 13 Changes in protein expression after treatment with Ancylostoma caninum excretory/secretory products in a mouse model of colitis -- Full text | PDF
- 2016 Dec Effect of Helminthic Infection on the Prevention and Treatment of Inflammatory Bowel Disease and the Mechanisms (IBD)
- 2016 Nov 18 Treatment with Cestode Parasite Antigens Results in Recruitment of CCR2+ Myeloid Cells, the Adoptive Transfer of Which Ameliorates Colitis -- Full text | PDF (HDC)
- 2016 Oct 15 Mucosal and systemic immune modulation by Trichuris trichiura in a self-infected individual
- Colonisation by the human whipworm, Trichuris trichiura, showed several indicators of mucosal and systemic immune modulation.
- 2016 Oct 5 A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's disease -- Full text | PDF This trial employed a novel TSO formulation with a pH of 5, when it is known that storage of TSO at a pH above 4 may impede its therapeutic effect in humans. [1] The conclusions drawn by the authors of this study about the efficacy of TSO are therefore not reliable.
- ✅2016 Apr 14 Helminth infection promotes colonization resistance via type 2 immunity -- Full text | PDF (Science)
(Also see this explanatory video: Worm infection counters intestinal inflammation by changing gut microbiome.)
- 2016 Apr 14 Parasitic worms may prevent Crohn’s disease by altering bacterial balance -- Mitch Leslie, Science. (Also reported by Science Daily. [2])
- 2016 Apr 7 IL-22 Restrains Tapeworm-Mediated Protection against Experimental Colitis via Regulation of IL-25 Expression -- Full text | PDF
- ✅⚡2015 Apr 18 Overcoming Evolutionary Mismatch by Self-Treatment with Helminths: Current Practices and Experience (PDF)
- 2014 Dec The emerging role of helminths in treatment of the inflammatory bowel disorders -- PDF (IBD)
- 2014 Winter Potential treatment of inflammatory bowel disease: a review of helminths therapy -- Full text | PDF (IBD)
- 2014 Oct 1 Helminth infections decrease host susceptibility to immune-mediated diseases -- Full text | PDF
- 2014 Aug 24 Extraintestinal helminth infection reduces the development of colitis-associated tumorigenesis -- Full text | PDF (IBD) (Cancer)
- 2014 Jan 20 Helminth therapy (worms) for induction of remission in inflammatory bowel disease -- Full text | PDF (IBD)
- 2013 Oct 22 Colitis promotes adaptation of an intestinal nematode: a Heligmosomoides polygyrus mouse model system -- Full text | PDF
- 2013 Mar Childhood helminth exposure is protective against inflammatory bowel disease: a case control study in South Africa (IBD)
- 2012 Oct Nematode modulation of inflammatory bowel disease -- Full text | PDF (IBD)
- 2012 Aug Heligmosomoides polygyrus abrogates antigen-specific gut injury in a murine model of inflammatory bowel disease -- Full text | PDF
- 2011 Sept 27 Toll-like receptor activation by helminths or helminth products to alleviate inflammatory bowel disease -- Full text | PDF (IBD)
- 2010 Dec 1 IL-22+ CD4+ T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis patient -- PDF
- An individual who self-infected with Trichuris trichiura ova (TTO) experienced almost complete remission of his colitis symptoms.
- 2010 Effect of hookworm treatment on active Crohn's disease (Only an abstract appears to have been published.)
- 2009 Sept 16 Infection with Hymenolepis diminuta is more effective than daily corticosteroids in blocking chemically induced colitis in mice -- Full text | PDF
- Infection with Hymenolepis diminuta cysticercoids (HDC) was found to be superior to daily corticosteroids in the prevention of colitis in mice, and did not result in additional side effects.
- 2009 Jul Advances in the pathogenesis and treatment of IBD -- Full text | PDF
- ✅⚡2009 Jan Helminths and the IBD hygiene hypothesis
- 2008 May 21 Worms and the treatment of inflammatory bowel disease: are molecules the answer? -- Full text | PDF (IBD)
- 2008 Jan 14 Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature -- Full text | PDF (IBD)
- 2008. This year saw the start of a large, decade-long, research programme involving twelve trials set up to investigate the effects of TSO in several diseases, including IBD. The entire programme was doomed by fundamental failures in study design, and all but three of the trials were discontinued prematurely, ostensibly due to a lack of beneficial effect. Unfortunately, the large number of trials involved, and the lack of understanding of the trials' design flaws by the vast majority of commentators, including members of the medical profession, has led to the widespread, albeit incorrect, belief that TSO is ineffective as a therapy. For more detail about this flawed research programme, see The history of helminthic therapy: 2008.
- 2006 Oct-Dec Intestinal helminths: a clue explaining the low incidence of inflammatory bowel diseases in Subsaharan Africa? Potential benefits and hazards of helminth therapy (IBD)
- ✅ 2006 Jan A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors -- Full text | PDF Investigated whether Crohn’s disease patients would tolerate a hookworm infection, and the practical issues associated with establishing reservoir donors for this species. (NA)
- 43.3% of patients with active ulcerative colitis who were given TSO showed improvement, in comparison with only 16.7% of those receiving a placebo.
- 2005 Feb Gastrointestinal parasites: potential therapy for refractory inflammatory bowel diseases (IBD)
- 2005 Jan Will worms really cure Crohn's disease? -- Full text | PDF (see pages 6-8)
- ✅ 2005 Jan Trichuris suis therapy in Crohn's disease -- Full text | PDF
- 79% of patients with Crohn’s disease who were given Trichuris suis ova (TSO) responded with a significant reduction in symptoms.
- 2004 Dec 14 Parasitic worms may offer effective treatment for Crohn's disease Medical News Today
- ✅ 2003 Sept Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease
- The safety and efficacy of treatment with TSO was demonstrated in patients with Crohn’s disease and ulcerative colitis.
- ✅ 2000 Sept 14 Does the failure to acquire helminthic parasites predispose to Crohn's disease? -- Full text | PDF This paper linking a failure to acquire helminths to the prevalence of Crohn’s disease was key in the development of the Hygiene Hypothesis.
- 1999 In Pursuit of Autoimmune Worm Cure. Andy Newman, New York Times.
- ✅ 1979 Apr Epidemiology of chronic intestinal disease in middle Africa This was one of several papers noting a North-South gradient for many autoimmune diseases, including Crohn’s, a fact that informed later studies on autoimmunity.
See also (not directly related)
- 2024 Mar 6 Giardia intestinalis reshapes mucosal immunity toward a Type 2 response that attenuates inflammatory bowel-like diseases -- Full text | PDF (preprint)
For more research papers on helminthic therapy and IBD, search the following page for the terms, “Crohn” or "colitis", “bowel” and “IBD”.
Limitations of helminthic therapy in treating IBD[edit | edit source]
Previous structural damage cannot be reversed[edit | edit source]
While the disease process can be arrested by helminthic therapy, any structural damage, such as scarring and strictures that have already formed as a result of disease, cannot be undone by hosting helminths.
Duration and severity of illness, and age of patient, can restrict benefits[edit | edit source]
A favourable outcome is more likely in those who are young, have a less severe form of the disease, and have had their illness for a shorter period of time. For example, among self-treaters using NA who are "very sick" with IBD, the treatment is only successful in about 40% of cases of ulcerative colitis and 65% of Crohn’s disease patients. [3]
Intestinal fistulae and abscesses are likely to require conventional treatment[edit | edit source]
Helminths subdue inflammation over time by gradually calming the immune response, but this effect is too subtle to deal with acute inflammation or its consequences. Therefore helminths are unlikely to be able to treat fistulae or abscesses without the use of surgery and/or medication. (The gastric pentadecapeptide, BPC 157 (Bepecin), may also be worth consideration. [4] [5] [6]) Once these conditions have been brought under control, however, the immunomodulation provided by helminths may prevent the development of further abscesses or fistulae.
One helminth self-treater has reported that, after having a fistula surgically corrected prior to starting helminthic therapy, she was mostly in remission for the subsequent 7 years, topping up her helminth colony whenever her symptoms began to return. [7]
It is not ideal to start helminthic therapy while IBD is flaring[edit | edit source]
The introduction of helminths triggers a response from the host's immune system, and this can increase intestinal inflammation during the first 100 days of treatment, peaking at around 50 days. This inflammatory response, which is largely dose-dependent, may temporarily worsen an existing flare. It is therefore best to commence helminthic therapy while IBD is quiescent, or to take an immunosuppressant drug alongside the therapy until any additional inflammation resolves. If this is not possible, advice should be sought from a helminthic therapy-literate medical practitioner and/or an experienced helminth provider.
Helminthic therapy may take up to two years to deliver consistent results[edit | edit source]
While consistent results are typically seen in a matter of months, they can take much longer to materialise in a few cases, especially when using the human helminths, NA and TTO. The pig whipworm, TSO, produces results more quickly. For further details about the response times of each species, see the following links.
It will be obvious from the above that it is not a good idea to "save" helminthic therapy as a treatment of last resort. Commencing helminthic therapy as soon as possible will increase the chance of success, and many people have expressed considerable regret that they delayed getting started with this therapy.
Helminthic therapy is compatible with conventional IBD therapies[edit | edit source]
Helminthic therapy is fully compatible with the use of immunosuppressive drugs. See the following page section for more details.
Someone with ulcerative colitis who saved his colon and eventually got off all systemic high-risk immunosuppressive medications by hosting worms, does continue to take a high dose of Balsalazide in addition to maintaining his helminth colony.

The absence of regulatory approval belies the confidence of some researchers and clinicians[edit | edit source]
No mainstream medical doctor is able to offer or officially condone helminthic therapy, or support its use, because it has not yet been approved for clinical use by any national regulatory body outside Thailand. [9] And regulatory approval is unlikely to be forthcoming in other countries in the foreseeable future because the fact that living helminths cannot be patented makes it all but impossible to obtain funding for the type of trials demanded by regulators.
There have also been significant failures in the design of many of the clinical trials that been conducted previously using living helminths, to the extent that the conclusions from the majority of the most recent trials cannot be relied upon, as is explained in the following section of this wiki.
Most gastroenterologists remain unaware of this treatment, and those who lack an appreciation of the issues with much of the research may dismiss it as unproven, or even claim it to be potentially harmful. However, this position by medics does not prevent patients from using the therapy, which is essentially not a medical treatment. It is a natural replacement therapy used to correct a helminth deficiency, and, as such, it is already available for use at home by patients employing one or more safe "probiotic" helminths.

There are many doctors who are already using helminthic therapy as a self-treatment to address their own health issues (e.g., this pathologist) and those of their families, and scientists who have thoroughly investigated helminthic therapy have no reservations about treating themselves with worms.

Selecting a suitable helminth for IBD[edit | edit source]
Many self-treaters have found that TSO and NA are both very effective against Crohn’s disease, and that colitis responds well to either TSO or TTO. Some colitis patients have reported success using NA, either alone, or in combination with TTO or TSO, and a few have had good results treating both Crohn's and colitis with HDC. For more details about helminth selection, see the following page.
Support for IBD patients using helminthic therapy[edit | edit source]
To talk with people who are using helminths to treat Crohn's disease or ulcerative colitis, join the following support group.
To book an educational consultation with either a medical professional, or a specialist health coach, who is experienced in the use of helminthic therapy, see the following list.
Further reading[edit | edit source]
Given that helminthic therapy can take a while to begin producing benefits (up to 2 years in the case of NA [12]) it can help to have alternative treatment options to turn to while waiting for the worms to begin to work. The following two documents contain a wealth of mostly science-based, natural alternatives.